⟵ Back to Search Results

BGB-A317-301

Completed

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

Beigene Study ID info

BGB-A317-301

ClinicalTrials.gov ID info

NCT03412773

EudraCT Number info

2017-002423-19

China Drug Trials ID info

CTR20170882

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents